5 withdrawn. 5 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Withdrawn 5 |
| Phase 1 | 1 | Withdrawn 1 |
Follow Myelofibrosis: new trials by email Literature Review of Myelofibrosis trials Research Report on Myelofibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2 Study of INCB57643 (BET Inhibitor) in Combination With Ruxolitinib in JAK Inhibitor-naïve Patients With Myelofibrosis Ruxolitinib, INCB57643 - Myelofibrosis | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2024-09-11 | 2025-05-22 | |
| Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation Anti-Thymocyte Globulin, Busulfan, Cyclophosphamide - Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Withdrawn | Fred Hutchinson Cancer Center | 2021-06-01 | 2021-06-30 | |
| A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy APG-1252, Ruxolitinib - Myelofibrosis | Phase 1 / Phase 2 | Withdrawn | Ascentage Pharma Group Inc. | 2020-12-15 | 2022-07-12 | |
| Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant Multi-antigen CMV-Modified Vaccinia Ankara Vaccine, Laboratory Biomarker Analysis, Placebo - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia in Remission | Phase 2 | Withdrawn | City of Hope Medical Center | 2018-12-01 | 2018-11-21 | |
| Creation of Bone Marrow Microenvironment for Treatment of Myelodysplastic Syndrome (MDS) in Conjunction With Allogeneic Stem Cell Transplantation DBM for creation of bone marrow microenvironment - Myelodysplastic Syndromes, Myelofibrosis | Phase 2 | Withdrawn | Hadassah Medical Organization | 24 | 2003-04-01 | 2011-04-28 |
Primary Myelofibrosis (5) · Myelodysplastic Syndromes (3) · Hodgkin Disease (2) · Leukemia, Myeloid, Chronic-Phase (2) · Lymphoma, Non-Hodgkin (2) · Myeloproliferative Disorders (2) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myeloid, Accelerated Phase (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Myelomonocytic, Chronic (1) · Polycythemia Vera (1) · Thrombocytosis (1)
Bone Marrow Diseases (5) · Hematologic Diseases (5) · Hemic and Lymphatic Diseases (5) · Myeloproliferative Disorders (3) · Neoplasms (3) · Chronic Disease (2) · Disease Attributes (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Leukemia (2) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Leukemia, Myeloid (2) · Lymphatic Diseases (2) · Lymphoma (2) · Lymphoproliferative Disorders (2)
ruxolitinib (2) · Antilymphocyte Serum (1) · Busulfan (1) · Cyclophosphamide (1) · Cyclosporine (1) · Cyclosporins (1) · Methotrexate (1) · Peripheral Blood Stem Cell Transplantation (1) · Tacrolimus (1) · Whole-Body Irradiation (1) · fludarabine phosphate (1) · merphos (1) · pelcitoclax (1)
Ascentage Pharma Group Inc. (1) · City of Hope Medical Center (1) · Fred Hutchinson Cancer Center (1) · Hadassah Medical Organization (1) · M.D. Anderson Cancer Center (1)
United States (3) · Israel (1)
Mahesh Swaminathan, MBBS (1) · Masumi Ueda Oshima (1) · Olga Gurevitch, PhD (1) · Ryotaro Nakamura, MD (1) · Yifan Zhai, MD, PhD (1)